Brian Klein

Stifel analyst Brian Klein published abstracts Thursday from the 2015 ASCO annual meeting. Klein’s following comments along with current ratings were intended to provide investors with “meaningful insight into ongoing clinical activities for various investigational agents.”...

Pharmacyclics, Inc. (NASDAQ: PCYC) reported Q4 results on Wednesday and posted adjusted of EPS $0.96, above estimates of $0.76, on revenues of $290.2 million. The company also reaffirmed its fiscal 2015 outlook. JP Morgan analyst Cory Kasimov felt that the company’s long-term future...

In a report published Monday, Stifel analyst Brian Klein terminated coverage on Oncolytics Biotech (NASDAQ: ONCY). In the report, Stifel noted, "Due to a reallocation of resources, we are discontinuing coverage of Oncolytics Biotech Inc. (ONCY). Our most recent rating of Hold should no longer be...

In a report published Monday, Stifel analyst Brian Klein terminated coverage on GTx, Inc. (NASDAQ: GTXI). In the report, Stifel noted, "Due to a reallocation of resources, we are discontinuing coverage of GTx Inc. (GTXI). Our most recent rating of Hold should no longer be used as an indicator for...

Stifel initiated coverage on Proteon Therapeutics Inc (NASDAQ: PRTO) Monday with a Buy rating and $17 price target. Analysts led by Brian Klein commented that "Proteon is set to enter the growing ESRD market with lead Phase 3 product PRT-201, in development to reduce vascular access...

In a report published Friday, Stifel analyst Brian Klein reiterated a Buy rating on Clovis Oncology (NASDAQ: CLVS), and raised the price target from $50.00 to $75.00. In the report, Stifel noted, “Clovis reported a 3Q14 LPS of $(1.17) vs. our estimate of $(1.11); delta due to higher R&D expense...

Analysts at Stifel raised their price target on shares on Medivation Inc (NASDAQ: MDVN) to $112 from $89 on Thursday. On Wednesday, The FDA Approved Medivation’s Xtandi broadened label to expand treatment to metastatic castrate resistant prostate cancer (mCRPC) prior to chemotherapy....

In a report published Thursday, Stifel analyst Brian Klein upgraded the rating on Clovis Oncology (NASDAQ: CLVS) from Hold to Buy, and named a $50.00 price target. In the report, Stifel noted, “Following the significant pull-back of ~60% from recent highs, we believe Clovis now presents with...

In a report published Wednesday, Stifel analyst Brian Klein downgraded the rating on Synta Pharmaceuticals (NASDAQ: SNTA) from Hold to Sell. In the report, Stifel noted, “SNTA reported 4Q13 LPS of $(0.31), in line with our $(0.32) estimate. Due to further delayed data readouts, changes in clinical...

In a report published Monday, Stifel analyst Brian Klein initiated coverage on Celladon (NASDAQ: CLDN) with a Buy rating and $16.00 price target. In the report, Stifel noted, “We are initiating coverage of Celladon Corporation (CLDN) with a Buy rating and $16 target price. Mydicar is a one-time...

In a report published Friday, Stifel analyst Brian Klein initiated coverage on Sarepta Therapeutics (NASDAQ: SRPT) with a Buy rating and $51.00 price target. In the report, Stifel noted, “We are initiating coverage of Sarepta Therapeutics (SRPT) with a Buy rating and $51 target price, as we...

In a report published Friday, Stifel analyst Brian Klein initiated coverage on Clovis Oncology (NASDAQ: CLVS) with a Hold rating. In the report, Stifel noted, “While we view the early-stage clinical data for CO-1686 as encouraging, we believe the available dataset does not warrant the company's...

In a report published Monday, Stifel Nicolaus analyst Brian Klein initiated coverage on Esperion Therapeutics (NASDAQ: ESPR) with a Buy rating and $24.00 price target. In the report, Stifel Nicolaus noted, “We view ETC-1002 as an impressive cholesterol lowering agent that directly targets...